Skip to main content

Table 3 Single-nucleotide polymorphisms associated with breast cancer risk in postmenopausal women using estrogen-progestin therapy at baselinea

From: The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: a nested case-control study in the California Teachers Study cohort

   Never used HT Using ET Using EPT
Gene SNP Nb
(ww/wv/vv)
OR (95% CI) Pc Nb
(ww/wv/vv)
OR (95% CI) Pc Pintd Nb
(ww/wv/vv)
OR (95% CI) Pc
(PACTe; PACTf)
Pintd
SLCO1B1 rs4149013 114/12/1
148/20/1
0.79 (0.39-1.60) 0.51 199/31/0
245/31/0
1.20 (0.69-2.03) 0.54 0.51 393/71/1
373/27/1
2.31 (1.47-3.62) 0.0003
(0.002; 0.023)
0.019
SLCO1B1 rs976754 110/16/1
143/25/1
0.87 (0.45-1.67) 0.67 198/32/0
246/31/0
1.21 (0.71-2.05) 0.48 0.51 375/91/2
351/49/1
1.71 (1.19-2.47) 0.004
(0.045; 0.37)
0.11
SLCO1B1 rs11045777 86/35/6
104/56/8
0.68 (0.42-1.09) 0.11 155/66/9
180/82/14
0.88 (0.64-1.19) 0.40 0.42 327/131/10
248/134/19
0.72 (0.56-0.92) 0.009
(0.10; 0.68)
0.95
SLCO1B1 rs11045773 86/35/6
103/56/9
0.66 (0.41-1.06) 0.09 155/66/9
181/81/14
0.88 (0.65-1.20) 0.42 0.36 326/131/10
248/134/19
0.72 (0.56-0.92) 0.009
(0.11; 0.70)
0.86
  1. asingle-nucleotide polymorphisms that were associated with breast cancer risk with P values of less than 0.01 (uncorrected for multiple testing) in subgroup analyses of postmenopausal women who were using estrogen-progestin therapy at baseline. The odds ratios (ORs) and 95% confidence intervals (CIs) were based on conditional logistic regression models stratified by age group (within 5-year age groups) and specimen collection centers - the Cancer Prevention Institute of California, the University of Southern California, and the University of California at Irvine - using log-additive genetic models. bNumber of cases carrying 0, 1, and 2 copies of minor allele and number of controls carrying 0, 1, and 2 copies of minor allele, respectively. cP values not corrected for multiple testing. dP values for interaction with never hormone therapy (HT) users. ePACT (P value adjusted for correlated tests) was calculated within each gene by using the methods of Conneely and Boehnke [68]. fPACT was calculated across all genes by using the methods of Conneely and Boehnke [68]. CI, confidence interval; EPT, estrogen-progestin therapy; ET, estrogen-only therapy; OR, odds ratio; SNP, single-nucleotide polymorphism.